Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856802 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A Phase 2 study, sponsored by Upsher-Smith Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT02856802 is a Phase 2 study that has completed, run by Upsher-Smith Laboratories. The registered enrollment target is 107 participants.
The verdict
NCT02856802, a Phase 2 study, has completed, sponsored by Upsher-Smith Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
Interventions
- DRUG Sumatriptan 10 mg Nasal Spray
- OTHER Sumatriptan Placebo Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2017-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02856802
The ClinicalTrials.gov registry entry for NCT02856802 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Upsher-Smith Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sumatriptan 10 mg Nasal Spray is the first listed.
NCT02856802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02856802 about?
NCT02856802 is a clinical study titled "An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)". A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
What is the current status of trial NCT02856802?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2016-07-11. Estimated completion is 2017-02-10.
What interventions are being tested in trial NCT02856802?
The interventions under investigation include: Sumatriptan 10 mg Nasal Spray (DRUG), Sumatriptan Placebo Nasal Spray (OTHER).
Who is sponsoring clinical trial NCT02856802?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.